Literature DB >> 9987677

Opioids, NSAIDs and 5-lipoxygenase inhibitors act synergistically in brain via arachidonic acid metabolism.

M J Christie1, C W Vaughan, S L Ingram.   

Abstract

We have established that mu-opioid receptor activation causes a presynaptic inhibition of neurotransmitter release that is mediated by 12-lipoxygenase metabolites of arachidonic acid in midbrain neurons [1]. We further demonstrated that the efficacy of opioids was enhanced synergistically by treatment of brain neurons with inhibitors of the other major enzymes responsible for arachidonic acid metabolism; cyclooxygenase (COX-1) and 5-lipoxygenase. These findings explain a mechanism of analgesic action of NSAIDs in the central nervous system that is both independent of prostanoid release and inhibited by opioid antagonists, as well as the synergistic interaction of opioids with NSAIDs. These findings also suggest new avenues for development of centrally active medications involving combinations of lowered doses of opioids and specific 5-lipoxygenase inhibitors.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9987677     DOI: 10.1007/s000110050367

Source DB:  PubMed          Journal:  Inflamm Res        ISSN: 1023-3830            Impact factor:   4.575


  13 in total

1.  LOX inhibitor HOEC interfered arachidonic acid metabolic flux in collagen-induced arthritis rats.

Authors:  Wen Yang; Xia Wang; Liuxin Xu; Honglin Li; Rui Wang
Journal:  Am J Transl Res       Date:  2018-08-15       Impact factor: 4.060

Review 2.  Cannabinoids in the descending pain modulatory circuit: Role in inflammation.

Authors:  Courtney A Bouchet; Susan L Ingram
Journal:  Pharmacol Ther       Date:  2020-01-29       Impact factor: 12.310

3.  Analgesic, anti-inflammatory and anti-platelet activities of the methanolic extract of Acacia modesta leaves.

Authors:  Ishfaq A Bukhari; Rafeeq A Khan; Anwar H Gilani; Sagheer Ahmed; Sheikh Arshad Saeed
Journal:  Inflammopharmacology       Date:  2010-08       Impact factor: 4.473

4.  CC12, a P450/epoxygenase inhibitor, acts in the rat rostral, ventromedial medulla to attenuate morphine antinociception.

Authors:  Jennie L Conroy; Julia W Nalwalk; James G Phillips; Lindsay B Hough
Journal:  Brain Res       Date:  2013-01-05       Impact factor: 3.252

5.  Cyclooxygenase-2-specific inhibitor improves functional outcomes, provides neuroprotection, and reduces inflammation in a rat model of traumatic brain injury.

Authors:  Jonas J Gopez; Hongfei Yue; Ram Vasudevan; Amir S Malik; Lester N Fogelsanger; Shawn Lewis; David Panikashvili; Esther Shohami; Susan A Jansen; Raj K Narayan; Kenneth I Strauss
Journal:  Neurosurgery       Date:  2005-03       Impact factor: 4.654

6.  Cyclooxygenase-2 inhibition protects cultured cerebellar granule neurons from glutamate-mediated cell death.

Authors:  Kenneth I Strauss; Ann M Marini
Journal:  J Neurotrauma       Date:  2002-05       Impact factor: 5.269

Review 7.  Antiinflammatory and neuroprotective actions of COX2 inhibitors in the injured brain.

Authors:  Kenneth I Strauss
Journal:  Brain Behav Immun       Date:  2007-11-08       Impact factor: 7.217

8.  Placebo and Active Treatment Additivity in Placebo Analgesia: Research to Date and Future Directions.

Authors:  Matthew J Coleshill; Louise Sharpe; Luana Colloca; Robert Zachariae; Ben Colagiuri
Journal:  Int Rev Neurobiol       Date:  2018-08-06       Impact factor: 3.230

9.  Opioids activate brain analgesic circuits through cytochrome P450/epoxygenase signaling.

Authors:  Jennie L Conroy; Cheng Fang; Jun Gu; Scott O Zeitlin; Weizhu Yang; Jun Yang; Melissa A VanAlstine; Julia W Nalwalk; Phillip J Albrecht; Joseph E Mazurkiewicz; Abigail Snyder-Keller; Zhixing Shan; Shao-Zhong Zhang; Mark P Wentland; Melissa Behr; Brian I Knapp; Jean M Bidlack; Obbe P Zuiderveld; Rob Leurs; Xinxin Ding; Lindsay B Hough
Journal:  Nat Neurosci       Date:  2010-02-07       Impact factor: 24.884

10.  Altered behavioral phenotypes in soluble epoxide hydrolase knockout mice: effects of traumatic brain injury.

Authors:  Kenneth I Strauss; Artiom Gruzdev; Darryl C Zeldin
Journal:  Prostaglandins Other Lipid Mediat       Date:  2012-08-16       Impact factor: 3.072

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.